EarningsQ2 2026 Earnings Report

Medical Facilities (MFCSF) Q2 2026 Earnings Report

41 Followers

Previous Report: Q1 2026

MFCSF Q2 2026 EPS Results

Actual EPS$0.09

Consensus EPS$0.18

Beat/MissMissed by -$0.09

One Year Ago EPS$0.20

MFCSF Q2 2026 Revenue Results

Actual Revenue$61.26M

Expected Revenue$64.60M

Beat/MissMissed by -$3.34M

YoY Revenue Growth-21.71%

Earnings Announcement Details

QuarterQ2 2026

Date08/06/2026

TimeBefore Open

Conference CallThursday, August 6, 2026

MFCSF Upcoming Earnings

Medical Facilities's next earnings date is estimated for November 5, 2026, based on past reporting schedules.

Q2 2026 Earnings Call Audio

MFCSF Q2 2026 Earnings Call

0:00 / 0:00

Q2 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q2 2026 Earnings Call Summary

Q2 2026

Earnings Call Date:Aug 06, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call presented a generally positive operational and financial update: revenue, income from operations, and EBITDA all grew year-over-year, liquidity is strong with no corporate-level debt, and shareholder returns remain substantial via buybacks. However, the company faces notable volume softness in certain categories (inpatient, observation, pain management), and operating costs rose materially, which temper the outlook. Overall the positives—top-line and profit growth, strong cash position, and committed capital returns—outweigh the headwinds from volume mix and expense pressures.

Company Guidance

Management provided limited forward-looking numeric guidance, instead emphasizing balance-sheet flexibility and a continued priority on returning capital to shareholders: they repurchased ~1.34 million shares for $17.1M in Q2 (≈1.66M for $21M in H1) and have since fully used the current NCIB limit of ≈1.81M shares, contributing to a cumulative CAD 218M returned since Q3 2022; cash at quarter end was $64.1M (including $58M at corporate), consolidated net working capital was $65.2M (vs. $54.0M at year-end Dec.; cash then $43.4M), and the company has no corporate-level bank debt after paying off its credit facility in 2024. Operational context for that guidance included revenue of $63.1M (up 7.8%), income from operations of $9.6M (up 9.4%), EBITDA of $12.5M (up 7.1%), operating expenses up $3.8M (7.6%) with drugs & supplies +12.5%, salaries & benefits +6.4% and G&A +3.8%; surgical volume was down 2.3% (essentially flat excluding low‑margin dental), outpatient +0.9%, inpatient -12.5%, observation -9.1%, and pain management -19.9% (with new pain and orthopedic physicians joining in September), and management said it will continue supporting hospitals while evaluating the most efficient ways to return capital.

Revenue Growth

Quarterly revenue of $63.1 million, up 7.8% year-over-year driven primarily by favorable payer and case mix toward higher-value orthopedic and spine procedures.

Improved Profitability

Income from operations increased 9.4% to $9.6 million and EBITDA grew 7.1% to $12.5 million year-over-year.

Strong Capital Returns to Shareholders

Repurchased ~1.34 million common shares for $17.1 million in the quarter (1.66 million shares for $21 million in H1), and subsequently fully utilized the ~1.81 million share NCIB limit. Cumulative returns to shareholders since Q3 2022 of approximately CAD 218 million via NCIBs, substantial issuer bids, and dividends.

Robust Liquidity Position

Consolidated cash balance of $64.1 million (including $58.0 million at the corporate level) and consolidated net working capital of $65.2 million, up from $54.0 million at year-end December; cash increased from $43.4 million at Dec year-end to $64.1 million.

No Corporate-Level Bank Debt

Operating with no corporate-level bank debt after fully paying off the corporate credit facility in 2024, providing balance sheet flexibility.

Operational Staffing and Physician Additions

Active recruitment yielding results: Arkansas Surgical Hospital added a new pain physician and will have a new orthopedic surgeon starting in September, addressing prior volume shortfalls.

MFCSF Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change
Nov 05, 2026	2026 (Q3)	0.12 / -	0.23	―
Aug 06, 2026	2026 (Q2)	0.18 / 0.09	0.2	-55.00% (-0.11)
May 07, 2026	2026 (Q1)	1.41 / 0.21	0.17	23.53% (+0.04)
Mar 12, 2026	2025 (Q4)	0.35 / 0.15	0.59	-74.58% (-0.44)
Nov 06, 2025	2025 (Q3)	0.27 / 0.23	0.3	-23.33% (-0.07)
Aug 07, 2025	2025 (Q2)	0.21 / 0.20	-0.02	1100.00% (+0.22)
May 08, 2025	2025 (Q1)	0.22 / 0.17	0.07	142.86% (+0.10)
Mar 13, 2025	2024 (Q4)	0.41 / 0.59	0.39	51.28% (+0.20)
Nov 07, 2024	2024 (Q3)	0.50 / 0.30	-0.01	3100.00% (+0.31)
Aug 06, 2024	2024 (Q2)	0.30 / -0.02	0.13	-115.38% (-0.15)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed